Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired.
The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on Dec. 24, 2021.
Get the full story at our sister site, Drug Delivery Business News.